

August 4, 2014

Mountain View, California

SANBIO ANNOUNCES THE APPOINTMENT OF CHIEF MEDICAL OFFICER

SanBio, Inc. today announced the appointment of Damien Bates, MD, PhD as Chief Medical Officer of the Company. Previously, Dr. Bates served as Global VP Medical Affairs at Allergan Medical in Irvine, CA and as VP and Chief Medical Officer at Organogenesis in Canton, MA. Dr. Bates replaces Dr. Ernest Yankee who is retiring. Dr. Yankee will continue to serve SanBio as a consultant.

Keita Mori, CEO of SanBio said, "We are delighted to welcome Dr. Bates to our management team. Dr. Bates brings vast experience and a successful track record in regenerative medicine, including leading the first and only BLA approval of an allogeneic cell therapy product. As SanBio is now moving into late stage clinical development for our first cell therapy product, SB623, Dr. Bates' knowledge and experience will be invaluable and critical to our future success."

In reflecting upon Dr. Yankee's service to the Company, Mr. Mori said, "I cannot overstate the importance of the contributions of Dr. Ernest Yankee during his 7 years of service to SanBio. At SanBio, Dr. Yankee led the development of our innovative cell therapy product, SB623, and achieved the Company's first IND approval for SB623. Dr. Yankee then led the Phase 1/2 clinical study of SB623 achieving 'proof of concept' in stable stroke patients. Dr. Yankee is retiring from over 40 years of dedicated service to the biotechnology and pharmaceutical industries, including at Upjohn, where he significantly contributed to obtaining marketing approval for a number of products, including Zyvox[®], Rescriptor[®], Cleocin, and Covert[®]."

As Chief Medical Officer, Dr. Bates will oversee all clinical and regulatory activities of the Company and will be a member of SanBio's Management Committee.

SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products. SanBio's first product, SB623, is a proprietary allogeneic cell therapy product consisting of cells derived from bone marrow. SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

Contact:

Keita Mori, CEO
SanBio Inc.
231 S. Whisman Road
Mountain View, CA 94041
keita.mori@san-bio.com
www.san-bio.com